Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Tyk2

Tyk2

Brief Information

Name:Tyrosine-protein kinase 2
Target Synonym:EC:2.7.10.2,TYK2,Tyrosine Kinase 2,Non-Receptor Tyrosine-Protein Kinase TYK2,EC 2.7.10.2,IMD35,JTK1,TYK2 Kinase,EC 2.7.10
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:8
Lastest Research Phase:Approved

Synonym Name

Tyk2,tyrosine kinase 2

Background

Tyk2 was the first member of the JAK family that was described (the other members are JAK1, JAK2, and JAK3). It has been implicated in IFN-?, IL-6, IL-10 and IL-12 signaling. Tyk2 functions primarily in IL-12 and type I-IFN signaling. Tyk2 deficiency has more dramatic effects in human cells than in mouse cells. However, in addition to IFN-? and -? and IL-12 signaling, Tyk2 has major effects on the transduction of IL-23, IL-10, and IL-6 signals. Recently, it has been recognized that IL-12 and IL-23 share ligand and receptor subunits that activate Tyk2. Tyk2 is activated by IL-10, and its deficiency affects the ability to generate and respond to IL-10.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Peficitinib ASP-015K; JNJ-54781532 Approved Astellas Pharma Inc Smyraf Japan Arthritis, Rheumatoid Astellas Pharma Inc 2019-03-29 Arthritis, Rheumatoid Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
ABBV-712 ABBV-712 Phase 1 Clinical Abbvie Inc Psoriasis Details
ICP-332 ICP-332 Phase 1 Clinical InnoCare Pharma Ltd Psoriasis; Dermatitis, Atopic Details
ESK-001 ESK-001 Phase 1 Clinical Alumis Inc Autoimmune Diseases; Psoriasis Details
TQ-05105 TQ-05105 Phase 2 Clinical Lianyungang Runzhong Pharmaceutical Co Ltd, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd, Centaurus Biopharma Co Ltd Neoplasms; Graft vs Host Disease; Myeloproliferative Disorders; Primary Myelofibrosis; Lymphohistiocytosis, Hemophagocytic Details
NDI-034858 NDI-034858 Phase 2 Clinical Nimbus Therapeutics Plaque psoriasis Details
MAX-40070 MAX-40070 Phase 1 Clinical Maxinovel Pty Ltd Alopecia Areata Details
TLL-018 TLL-018 Phase 2 Clinical Tll Pharmaceutical Arthritis, Rheumatoid; Chronic Urticaria; Psoriasis; Urticaria Details
Ropsacitinib PF-06826647 Pfizer Pharmaceuticals Ltd (China) Details
GLPG-3667 GLPG-3667 Galapagos Nv Details
Brepocitinib PF-06700841-15; PF-6700841; PF-841; PF-06700841 Phase 3 Clinical Pfizer Inc Alopecia; Alopecia Areata; Dermatomyositis; Lupus Erythematosus, Systemic; Psoriasis; Colitis, Ulcerative; Arthritis, Psoriatic; Hidradenitis Suppurativa; Dermatitis, Atopic; Vitiligo; Crohn Disease Details
GLPG-3121 GLPG-3121 Phase 1 Clinical Galapagos Nv Details
OST-122 OST-122 Phase 2 Clinical Oncostellae Colitis, Ulcerative Details
BGB-23339 BGB-23339 Phase 1 Clinical Beigene Ltd Autoimmune Diseases; Plaque psoriasis Details
ICP-488 ICP-488 Phase 1 Clinical InnoCare Pharma Ltd Autoimmune Diseases; Psoriasis; Plaque psoriasis Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message